全文获取类型
收费全文 | 91篇 |
免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
基础医学 | 5篇 |
口腔科学 | 1篇 |
临床医学 | 6篇 |
内科学 | 11篇 |
特种医学 | 3篇 |
外科学 | 12篇 |
综合类 | 24篇 |
预防医学 | 2篇 |
眼科学 | 5篇 |
药学 | 15篇 |
中国医学 | 3篇 |
肿瘤学 | 5篇 |
出版年
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 3篇 |
2015年 | 2篇 |
2014年 | 3篇 |
2013年 | 7篇 |
2012年 | 6篇 |
2011年 | 5篇 |
2010年 | 18篇 |
2009年 | 7篇 |
2008年 | 9篇 |
2007年 | 7篇 |
2005年 | 1篇 |
2004年 | 4篇 |
2003年 | 1篇 |
2001年 | 1篇 |
2000年 | 2篇 |
1997年 | 1篇 |
1991年 | 1篇 |
排序方式: 共有94条查询结果,搜索用时 109 毫秒
1.
Amit Goel Dharmendra Singh Bhadauria Anupma Kaul Narayan Prasad Amit Gupta Raj Kumar Sharma Praveer Rai Rakesh Aggarwal 《Indian journal of gastroenterology》2017,36(2):137-140
In recent past, direct-acting anti-viral drugs (DAAs) have become the standard of care for the treatment of hepatitis C virus (HCV) infection. However, the experience with the use of these drugs in Indian renal transplant recipients is limited. We retrospectively reviewed our experience with DAA-based treatment for HCV infection in such patients. Between April 2015 and December 2016, six adults (median age 41 [range 34–52] years, male 5; GT1 2, GT3 3, and GT4 1; including three with prior failed interferon-based treatment) had received genotype-guided, DAA-based anti-HCV treatment 1 to 158 (median 15) months after renal transplantation. Of them, four completed the planned 24-week treatment without any significant adverse event. One of them had increase in serum creatinine after 16 weeks of treatment with sofosbuvir and daclatasvir, with acute interstitial nephritis on kidney biopsy; his renal function improved on stopping the drugs. The other patient had preexisting mild renal dysfunction, which worsened after 8 weeks of sofosbuvir-ledipasvir treatment; this did not reverse on stopping treatment. All the six patients achieved undetectable HCV RNA after 4 weeks of treatment and also achieved sustained virologic response, i.e. lack of detectable HCV RNA in serum 12 weeks after stopping treatment. Overall, DAA-based treatment was effective in treating HCV infection in our renal transplant recipients; however, caution and monitoring of renal function during such treatment is advisable in patients who have additional factors that predispose to renal injury. 相似文献
2.
Urinary Kidney injury molecule‐1 can predict delayed graft function in living donor renal allograft recipients 下载免费PDF全文
3.
4.
5.
6.
Singh Vishwajeet Kudesia Rajdeep Bhadauria Seema 《Proceedings of the National Academy of Sciences, India. Section B.》2020,90(4):855-861
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences - In the present study, ten genotypes of Lablab purpureus L. Sweet bean were screened for genetic divergence by... 相似文献
7.
Influence of soybean administration on the bioavailability of carbamazepine and omeprazole was studied after single dose administration of soybean (10 g/kg p.o.) or after chronic administration of soybean (50% w/w mixed with normal feed) for 15 days in rats. Carbamazepine was administered orally at a dose of 10 mg/kg and omeprazole at a dose of 20 mg/kg. Soybean decreased the bioavailability of carbamazepine after both single dose and chronic administration. It produced a significant decrease in Cmax, Tmax, AUC0–t of carbamazepine after single dose administration and increased the plasma clearance and Vd along with decrease in Cmax, Tmax, AUC0–t and AUC0– ∞ after chronic administration. On the contrary, soybean administration increased the bioavailability of omeprazole by producing an increase in Cmax, AUC0–t and AUC0– ∞ and a decrease in Vd after single dose administration and a decrease in plasma clearance along with increase in Cmax, AUC0–t and AUC0– ∞ after chronic administration. The half‐life of omeprazole was also increased after both acute and chronic administration of soybean. It was concluded that soybean decreases the bioavailability of carbamazepine and increases the bioavailability of omeprazole after both single dose and chronic administration. 相似文献
8.
9.
ObjectiveTo study the isolation and characterization of the constituent responsible for the cytotoxic activity of the ethanolic extract of stem of Capparis decidua (C. decidua).MethodsThe preliminary cytotoxic effect of isolated compound (β-Sitosterol triacontenate) was investigated by MTT assay on A549 solid tumor cells.ResultsIC50 value of the β-Sitosterol triacontenate was found to be 1 μM. The cytotoxic activity increased in a dose dependent manner in case of β-Sitosterol triacontenate.ConclusionsThe data therefore provide direct evidence for the role of β-Sitosterol triacontenate as a potent antimetastatic agent, which can markedly inhibit the metastatic and invasive capacity of malignant cells. 相似文献
10.
Narayan Prasad Archana Sinha Amit Gupta Raj Kumar Sharma Dharmendra Bhadauria Abhilash Chandra Kashi Nath Prasad Anupama Kaul 《Peritoneal dialysis international》2014,34(4):399-408
♦ Objectives: We studied the effect of body mass index (BMI) at peritoneal dialysis (PD) initiation on patient and technique survival and on peritonitis during follow-up.♦ Methods: We followed 328 incident patients on PD (176 with diabetes; 242 men; mean age: 52.6 ± 12.6 years; mean BMI: 21.9 ± 3.8 kg/m2) for 20.0 ± 14.3 months. Patients were categorized into four BMI groups: obese, ≥25 kg/m2; overweight, 23 - 24.9 kg/m2; normal, 18.5 - 22.9 kg/m2 (reference category); and underweight, <18.5 kg/m2. The outcomes of interest were compared between the groups.♦ Results: Of the 328 patients, 47 (14.3%) were underweight, 171 (52.1%) were normal weight, 53 (16.2%) were overweight, and 57 (17.4%) were obese at commencement of PD therapy. The crude hazard ratio (HR) for mortality (p = 0.004) and the HR adjusted for age, subjective global assessment, comorbidities, albumin, diabetes, and residual glomerular filtration rate (p = 0.02) were both significantly greater in the underweight group than in the normal-weight group. In comparison with the reference category, the HR for mortality was significantly greater for underweight PD patients with diabetes [2.7; 95% confidence interval (CI): 1.5 to 5.0; p = 0.002], but similar for all BMI categories of nondiabetic PD patients.Median patient survival was statistically inferior in underweight patients than in patients having a normal BMI. Median patient survival in underweight, normal, overweight, and obese patients was, respectively, 26 patient-months (95% CI: 20.9 to 31.0 patient-months), 50 patient-months (95% CI: 33.6 to 66.4 patient-months), 57.7 patient-months (95% CI: 33.2 to 82.2 patient-months), and 49 patient-months (95% CI: 18.4 to 79.6 patient-months; p = 0.015). Death-censored technique survival was statistically similar in all BMI categories. In comparison with the reference category, the odds ratio for peritonitis occurrence was 1.8 (95% CI: 0.9 to 3.4; p = 0.086) for underweight patients; 1.7 (95% CI: 0.9 to 3.2; p = 0.091) for overweight patients; and 3.4 (95% CI: 1.8 to 6.4; p < 0.001) for obese patients.♦ Conclusions: In our PD patients, mean BMI was within the normal range. The HR for mortality was significantly greater for underweight diabetic PD patients than for patients in the reference category. Death-censored technique survival was similar in all BMI categories. Obese patients had a greater risk of peritonitis. 相似文献